

Editor's note: This English translation was done by a third party. The original report can be accessed [here](#).

**News
International and National in Drug Safety
October 2017**

**Pharmacovigilance Department
National Drug Administration
Food and Medical Technology
Republic of Argentina**

Finasteride, a testosterone-5- α reductase inhibitor: Controlling the risk of depression and suicidal ideation

(ANSM, France, 10/26/2017) Cases of depression and, more rarely, suicidal ideation have been observed in men treated with finasteride 1 mg for hair loss. The risk of depression is also associated with finasteride 5 mg, for the treatment of benign prostatic hypertrophy.

Patients and healthcare professionals are advised that any change in mood should lead to treatment discontinuation and monitoring. Also, ANSM reports that it is possible to observe a persistence of sexual disorders after discontinuing treatment with finasteride, which can be decreased libido, erectile dysfunction and ejaculation disorders. Additionally, cases of breast cancer have been reported in men treated with finasteride.

<https://archiveansm.integra.fr/S-informer/Points-d-information-Points-d-information/Finasteride-surveiller-le-risque-de-depression-et-d-idees-suicidaires-Point-d-information>

This information is complementary to that published by this department about suicidal risk with finasteride in the News of December 2015 and May 2017.

In the last three years (2014 to October 2017), the SNFVG [Argentinian National Pharmacovigilance System] has not received notifications of suspected adverse reactions of depression or suicidal ideation with finasteride.